Development of an algorithm for pancreatic cancer treatment using a combined DNA and RNA biomarker panel

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09033
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Okayama University
• Principal Investigator: Yoshida Ryuichi 岡山大学, 大学病院, 講師 (80534768)
• Co-Investigator(Kenkyū-buntansha): 香川 俊輔 岡山大学, 大学病院, 准教授 (00362971) ; 重安 邦俊 岡山大学, 大学病院, 助教 (70544071)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 膵癌

Outline of Final Research Achievements

Patients with mutKRAS-ctDNA detected preoperatively or postoperatively had a significantly poorer prognosis. Furthermore, a combined analysis of preoperative and postoperative mutKRAS-ctDNA detection status could be useful for detecting patients with liver recurrence.In addition, a significantly poor prognosis was observed in the group of patients with low GATA6 expression in primary tumors of pancreatic cancer.These results suggest that classification of pancreatic cancer patients according to biological risk factors could potentially determine the indications for surgery and the optimal timing of resection.

Free Research Field

膵癌

Academic Significance and Societal Importance of the Research Achievements

新規化学療法の実臨床への導入や切除可能性分類に従った診断体系の構築により膵癌治療成績は進歩しつつありますが、膵癌は現在でも極めて予後不良な難治癌です。
本研究では膵癌原発巣のRNA発現・ctDNA内遺伝子変異情報を用いた複合バイオマーカーパネルを作成し、真の切除適応や最適な切除時期の決定が可能となる膵癌治療アルゴリズムの構築を試みました。膵癌外科治療は多大な生体侵襲を伴うものであり、膵癌の生物学的悪性度が反映された治療アルゴリズムが実臨床に応用されるようになれば、膵癌患者さんにとって多大な福音となることが期待されています。